Menu
No results found.
185750
Chong Kun Dang Pharmaceutical Corp. – KRX
Weekly Share Price & Valuation Overview
Market Overview
Open
82700.0000
Close
82400.0000
High
82800.0000
Low
82100.0000
Trend
0.35008
Chong Kun Dang Pharmaceutical Corp.
South Korea
• KRX - Korea Stock Exchange
• 185750
• Currency: KRW
Chong Kun Dang Pharmaceutical Corp. engages in the manufacturing, marketing, and sales of medicines in South Korea and internationally. It provides prescription drugs for anticancer, anti-hypertension, anti-hyperlipidemia, anti-diabetic, and immunosuppressant products; over-the-counter drugs for therapeutic benefits, supplements, and other preventive products; health supplements with preventive benefits, including prebiotics and vitamins with Omega-3; and consumer health products, such as red-ginseng healthy drink, hand sanitizer, and hair color medication, as well as insecticides. The company also exports its products. Chong Kun Dang Pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.
Key strengths
- Revenue growth ≥10% indicates solid top-line momentum.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
Potential weaknesses
- Negative free cash flow — operations may rely on external financing.
Scale & Structure
Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
- Market Cap Total equity value of the company (share price × shares outstanding).
- KRW 1.09T
- Enterprise Value Operating value: market cap + total debt − cash.
- KRW 999.80B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- KRW 1.63T
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- KRW 523.49B
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- KRW 122.68B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- KRW 123.05K
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 1.33%
- Shares Outstanding
- 13.18M
- Float Shares
- 7.75M
- Implied Shares Outstanding
- 13.41M
Profitability & Efficiency
TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
3.11%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
7.55%
- Gross Margin (TTM) Reconciled Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
32.20%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
5.86%
- ROA Return on assets: net income ÷ total assets.
-
3.50%
- ROE Return on equity: net income ÷ shareholder equity.
-
11.24%
Growth
Growth rates are YoY unless labeled QoQ.
- Revenue Growth Strong Year-over-year revenue growth.
-
10.90%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-53.50%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-53.90%
Liquidity & Solvency
Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.49
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.21
- Total Cash Cash and equivalents.
- KRW 283.70B
- Total Debt Short + long-term interest-bearing debt.
- KRW 187.44B
- Net Debt Net Cash Total debt − cash (negative = net cash).
- KRW -96.26B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 1.53
Cash Flow
Shown only when internally consistent; margins are TTM.
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- KRW 12.52B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- KRW -115.14B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
0.77%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-7.08%
- Cash Conversion (OpCF/EBITDA)
- 0.10
Sharemaestro House View
Confidence: 1
Sharemaestro internal conviction (0–3, higher is better).
Risk: 3
Sharemaestro internal risk profile (0–3, higher is safer).
Operational: 1
Operational quality/consistency (0–3, higher is better).
Composite Score: 1
Overall internal composite (0–3, higher is better).
Suggested Allocation: 1.67%
Indicative portfolio weighting suggestion based on house view.
Structural Insights
(experimental)
Ownership & Liquidity
Free Float
Proportion of shares available for public trading.
58.8%
Insiders
Shares held by company insiders (officers, directors).
44.2%
Institutions
Shares held by institutions (funds, pensions).
19.4%
Capital Structure
Potential Dilution
Increase in share count if options/convertibles exercise.
1.8%
Net Debt
Total debt − cash (negative = net cash).
KRW -96.26B
-5.9% of revenue
Net debt relative to revenue — debt load vs business scale.
Resilience Score
0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating.
70
Methodology Notes
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 03:44
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.
AI generated insights not available yet. Sign in to generate the snapshot.